Cadrenal Therapeutics, Inc.
CVKD
$10.51
$1.6518.62%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 22.09% | 119.10% | 100.23% | 203.78% | 86.49% |
| Depreciation & Amortization | 0.00% | -20.00% | 816.67% | -33.33% | -33.33% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.13% | 51.39% | 123.74% | 238.53% | 115.30% |
| Operating Income | -11.13% | -51.39% | -123.74% | -238.53% | -115.30% |
| Income Before Tax | -11.54% | -53.25% | -131.19% | -265.99% | -132.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.54% | -53.25% | -131.19% | -265.99% | -132.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.54% | -53.25% | -131.19% | -265.99% | -132.30% |
| EBIT | -11.13% | -51.39% | -123.74% | -238.53% | -115.30% |
| EBITDA | -11.13% | -51.41% | -123.50% | -238.66% | -115.38% |
| EPS Basic | 39.76% | 16.62% | -33.80% | -138.77% | -115.98% |
| Normalized Basic EPS | 39.75% | 16.63% | -33.80% | -138.78% | -115.99% |
| EPS Diluted | 39.76% | 16.62% | -33.80% | -138.77% | -115.98% |
| Normalized Diluted EPS | 39.75% | 16.63% | -33.80% | -138.78% | -115.99% |
| Average Basic Shares Outstanding | 85.14% | 83.81% | 72.80% | 53.29% | 7.56% |
| Average Diluted Shares Outstanding | 85.14% | 83.81% | 72.80% | 53.29% | 7.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |